European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Search
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Serbia
Serbia
Latvia
Latvia
Lithuania
Lithuania
Israel
Israel
Bosnia and Herzegovina
Bosnia and Herzegovina
Survodutide (BI 456906): GLP1/GCGR agonist | MASH
Survodutide (BI 456906): GLP1/GCGR agonist | MASH
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Microbial Manufacturing Platform for Non-Platform Proteins
Microbial Manufacturing Platform for Non-Platform Proteins
Our Partners Harvard
Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
Duluth
Duluth
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, reflects on our philosophy and our impact on millions of lives.
Survodutide (BI 456906): GLP1/GCGR agonist | obesity
Survodutide (BI 456906): GLP1/GCGR agonist | obesity
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Pascal Haubert
Three months into an internship with us, Pascal Haubert talks about responsibility, learning, and mutual support.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.